4-allyl-5-hydroxy-2,3-dihydro-1H-inden-1-one | 320574-78-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 茚满类
• 英文名称: 4-allyl-5-hydroxy-2,3-dihydro-1H-inden-1-one
• 英文别名: 4-allyl-5-hydroxy-indan-1-one；5-hydroxy-4-prop-2-enyl-2,3-dihydroinden-1-one
• CAS: 320574-78-5
• 化学式: C₁₂H₁₂O₂
• 分子量: 188.226
• InChiKey: KMRVRUJQYTVJMR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-allyl-5-hydroxy-2,3-dihydro-1H-inden-1-one 在 间氯过氧苯甲酸 作用下， 以 二氯甲烷 为溶剂， 以89%的产率得到(±)-2-(hydroxymethyl)-7,8-dihydro-1H-indeno[5,4-b]furan-6(2H)-one
  参考文献：
  名称：

  Efficient synthesis and resolution of novel 2-(hydroxymethyl)-7,8-dihydro-1H-indeno[5,4-b] furan-6(2H)-one by lipase Pseudomonas cepacia

  摘要：

  Lipase Pseudomonas cepacia catalyzed acylation of (+/-)-2-(hydroxymethyl)-7,8-dihydro-1H-indeno[5,4-b] furan-6(2H)-one using vinyl acetate as the acyl donor in acetone gave (-)-(R)-2-acetoxy-2-(methyl)-7,8-dihydro-1H-indeno[5,4-b] furan-6(2H)-one and (+)-(S)-2-(hydroxymethyl)-7,8-dihydro-1H-indeno[5,4-b] furan-6(2H)-one with high enantiomeric excess. Enantiomerically pure 2-(hydroxymethyl)-7,8-dihydro-1H-indeno[5,4-b] furan-6(2H)-one are useful intermediates for the preparation of Ramelteon, an FDA approved drug for the treatment of insomnia. (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetasy.2014.02.008
• 作为产物：
  描述：

  5-allyloxy-indan-1-one 以 正己烷 、 乙酸乙酯 、 三氯苯 为溶剂， 以14.5%的产率得到4-allyl-5-hydroxy-2,3-dihydro-1H-inden-1-one
  参考文献：
  名称：

  5- substituted tetralones as inhibitors of ras farnesyl trransferase

  摘要：

  本发明提供了式(I)、(II)、(III)和(IV)的新型5-取代四酮及其药学上可接受的盐、酯、酰胺和前药，用于治疗和预防组织的不受控制或异常增殖，如癌症、动脉粥样硬化、再狭窄和银屑病。具体而言，本发明涉及抑制法尼基转移酶酶的化合物。

  公开号：

  US20040044057A1

文献信息

• 5-substituted tetralones as inhibitors of ras farnesyl transferase
  申请人：Denny William Alexander

  公开号：US06943183B2

  公开（公告）日：2005-09-13

  The present invention provides novel 5-substituted tetralones of Formulas I, II, III, and IV and pharmaceutically acceptable salts, esters, amides, and prodrugs thereof, which are useful for treating and preventing uncontrolled or abnormal proliferation of tissues, such as cancer, atherosclerosis, restenosis, and psoriasis. Specifically, the present invention relates to compounds that inhibit the farnesyl transferase enzyme

  本发明提供了式I、II、III和IV的新型5-取代四酮及其药学上可接受的盐、酯、酰胺和前药，用于治疗和预防组织的不受控制或异常增殖，如癌症、动脉粥样硬化、再狭窄和银屑病。具体来说，本发明涉及抑制法尼酰转移酶酶的化合物。
• 2-Aminothiazole allosteric enhancers of a ?1? adenosine receptors
  申请人：Linden Joel

  公开号：US20050027125A1

  公开（公告）日：2005-02-03

  The present invention relates generally to a class of 2-aminothiazole derivatives which have recently been identified as allosteric enhancers of the A 1? adenosine receptor. These compounds, and therapeutic compositions containing them, are useful for treating conditions in which activation of the A 1? adenosine receptor would be beneficial, for example, those conditions in which stimulation of angiogenesis would improve blood flow to ischemic tissues.

  本发明总体上涉及一类 2-氨基噻唑衍生物，这些衍生物最近被鉴定为 A 1?这些化合物以及含有它们的治疗组合物可用于治疗激活 A 1? 1? 腺苷受体将是有益的，例如，刺激血管生成将改善缺血组织的血流量。
• Predicting the Claisen rearrangement regioselectivity of allylindanyl and allyltetrahydronaphthalenyl ether derivatives by1H NMR experiments
  作者：Denise C. Rodrigues、Sergio A. Fernandes、Anita J. Marsaioli

  DOI：10.1002/1097-458x(200011)38:11<970::aid-mrc756>3.0.co;2-x

  日期：2000.11

  The regioselectivity of the Claisen rearrangement of allylindanyl and allyltetrahydronaphthalenyl ether derivatives can be predicted by conformational preference detected by H-1 NMR NOE difference spectra and T-1 measurements. Copyright (C) 2000 John Wiley & Sons, Ltd.
• 5-SUBSTITUTED TETRALONES AS INHIBITORS OF RAS FARNESYL TRANSFERASE
  申请人：WARNER-LAMBERT COMPANY

  公开号：EP1276725A2

  公开（公告）日：2003-01-22
• EP1583530A4
  申请人：——

  公开号：EP1583530A4

  公开（公告）日：2008-07-23